Matrix metalloproteinase enhances big-endothelin-1 constriction in mesenteric vessels of pregnant rats with reduced uterine blood flow

Hypertension

Volumn 61, Issue 2, 2013, Pages 488-493

  Abdalvand, Ali ^a   Morton, Jude S ^a   Bourque, Stephane L ^a   Quon, Anita L ^a   Davidge, Sandra T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

endothelin 1; matrix metalloproteinases; preeclampsia; reduced uterine perfusion pressure; vascular function

Indexed keywords

BIG ENDOTHELIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE A; GELATINASE B; ILOMASTAT; N(G) NITROARGININE METHYL ESTER; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; POTASSIUM SALT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; MESENTERY BLOOD VESSEL; NONHUMAN; PLACENTA CIRCULATION; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; UTERUS BLOOD FLOW; VASOCONSTRICTION;

ANIMALS; DIPEPTIDES; ENDOTHELIN-1; FEMALE; HEMODYNAMICS; MATRIX METALLOPROTEINASE 2; MESENTERIC ARTERIES; MESENTERY; NITRIC OXIDE; PRE-ECLAMPSIA; PREGNANCY; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; UTERUS; VASOCONSTRICTION;

EID: 84873060078     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.00055     Document Type: Article

References (29)

1. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130-137.
2. Reslan OM, Khalil RA. Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia. Cardiovasc Hematol Agents Med Chem. 2010;8:204-226.
3. George EM, Palei AC, Granger JP. Endothelin as a final common pathway in the pathophysiology of preeclampsia: therapeutic implications. Curr Opin Nephrol Hypertens. 2012;21:157-162.
4. Bernardi F, Constantino L, Machado R, Petronilho F, Dal-Pizzol F. Plasma nitric oxide, endothelin-1, arginase and superoxide dismutase in pre-eclamptic women. J Obstet Gynaecol Res. 2008;34:957-963.
5. Tam Tam KB, George E, Cockrell K, Arany M, Speed J, Martin JN Jr, et al. Endothelin type A receptor antagonist attenuates placental ischemia- induced hypertension and uterine vascular resistance. Am J Obstet Gynecol. 2011;204:330.e1-330.e4.
6. LaMarca B, Speed J, Fournier L, Babcock SA, Berry H, Cockrell K, et al. Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of tumor necrosis factor-alpha blockade. Hypertension. 2008;52:1161-1167.
7. D'Orléans-Juste P, Plante M, Honoré JC, Carrier E, Labonté J. Synthesis and degradation of endothelin-1. Can J Physiol Pharmacol. 2003;81:503-510.
8. Narumiya H, Zhang Y, Fernandez-Patron C, Guilbert LJ, Davidge ST. Matrix metalloproteinase-2 is elevated in the plasma of women with preeclampsia. Hypertens Pregnancy. 2001;20:185-194. (Pubitemid 33032126)
9. Montagnana M, Lippi G, Albiero A, Scevarolli S, Salvagno GL, Franchi M, et al. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J Clin Lab Anal. 2009;23:88-92.
10. Myers JE, Merchant SJ, Macleod M, Mires GJ, Baker PN, Davidge ST. MMP-2 levels are elevated in the plasma of women who subsequently develop preeclampsia. Hypertens Pregnancy. 2005;24:103-115. (Pubitemid 40911348)
11. Cohen M, Ribaux P, Epiney M, Irion O. Expression of metalloproteinases 1, 2, 7, 9, and 12 in human cytotrophoblastic cells from normal and preeclamptic placentas. Neuro Endocrinol Lett. 2012;33:406-411.
12. Benjamin MM, Khalil RA. Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. EXS. 2012;103:209-279.
13. Li J, LaMarca B, Reckelhoff JF. A model of preeclampsia in rats: the reduced uterine perfusion pressure (RUPP) model. Am J Physiol Heart Circ Physiol. 2012;303:H1-H8.
14. Morton JS, Abdalvand A, Jiang Y, Sawamura T, Uwiera RR, Davidge ST. Lectin-like oxidized low-density lipoprotein 1 receptor in a reduced uteroplacental perfusion pressure rat model of preeclampsia. Hypertension. 2012;59:1014-1020.
15. Crews JK, Herrington JN, Granger JP, Khalil RA. Decreased endothelium- dependent vascular relaxation during reduction of uterine perfusion pressure in pregnant rat. Hypertension. 2000;35(1 pt 2): 367-372. (Pubitemid 30054201)
16. Granger JP, LaMarca BB, Cockrell K, Sedeek M, Balzi C, Chandler D, et al. Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular- renal dysfunction in response to placental ischemia. Methods Mol Med. 2006;122:383-392.
17. Ramirez RJ, Debrah J, Novak J. Increased myogenic responses of resistance- sized mesenteric arteries after reduced uterine perfusion pressure in pregnant rats. Hypertens Pregnancy. 2011;30:45-57.
18. Walsh SK, English FA, Johns EJ, Kenny LC. Plasma-mediated vascular dysfunction in the reduced uterine perfusion pressure model of preeclampsia: a microvascular characterization. Hypertension. 2009;54: 345-351.
19. Bourque SL, Davidge ST, Adams MA. The interaction between endothelin- 1 and nitric oxide in the vasculature: new perspectives. Am J Physiol Regul Integr Comp Physiol. 2011;300:R1288-R1295.
20. Bourque SL, Whittingham HA, Brien SE, Davidge ST, Adams MA. Role of endothelin-1 in the hyper-responsiveness to nitrovasodilators following acute NOS inhibition. Br J Pharmacol. 2012;165:1992-1999.
21. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest. 1996;98:2572-2579. (Pubitemid 26415078)
22. Tronc F, Mallat Z, Lehoux S, Wassef M, Esposito B, Tedgui A. Role of matrix metalloproteinases in blood flow-induced arterial enlargement: interaction with NO. Arterioscler Thromb Vasc Biol. 2000;20:E120-E126.
23. Raoch V, Rodríguez-Pascual F, Lòpez-Martínez V, Medrano-Andrés D, Rodríguez-Puyol M, Lamas S, et al. Nitric oxide decreases the expression of endothelin-converting enzyme-1 through mRNA destabilization. Arterioscler Thromb Vasc Biol. 2011;31:2577-2585.
24. Yang G, Chang L, Alexander JS, Groome LJ, Yuping W. Chymotrypsinlike protease (chymase) mediates endothelial activation by factors derived from preeclamptic placentas. Reprod Sci. 2009;16:905-913.
25. Roggensack AM, Zhang Y, Davidge ST. Evidence for peroxynitrite formation in the vasculature of women with preeclampsia. Hypertension. 1999;33:83-89. (Pubitemid 29061846)
26. Anderson UD, Olsson MG, Kristensen KH, Åkerström B, Hansson SR. Review: biochemical markers to predict preeclampsia. Placenta. 2012;33 suppl:S42-S47.
27. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642-649. (Pubitemid 43865232)
28. Roberts L, LaMarca BB, Fournier L, Bain J, Cockrell K, Granger JP. Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion. Hypertension. 2006;47:615-618. (Pubitemid 43843885)
29. LaMarca BD, Ryan MJ, Gilbert JS, Murphy SR, Granger JP. Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Curr Hypertens Rep. 2007;9:480-485.